Drug Safety Concerns Shape Manufacturing Policy

FDA wants manufacturers to revise product labeling and packaging and step up adverse-event monitoring to reduce risky product use.

Related Content:

Regulatory WatchPharmaceutical Technology-03-02-2002

Advancing Global Collaboration for Drug Testing, Regulation, and Manufacturing

FDA In Limbo as User Fee Renewal Stuck on Capitol Hill

FDA Joins Effort to Curb Drug Patent Abuses